SLXP Share Price

Open 172.72 Change Price %
High 172.96 1 Day 0.16 0.09
Low 172.71 1 Week 0.00 0.00
Close 172.81 1 Month 0.00 0.00
Volume 4298146 1 Year 0.00 0.00
52 Week High 22.88
52 Week Low 17.40
SLXP Important Levels
Resistance 2 173.04
Resistance 1 172.95
Pivot 172.83
Support 1 172.67
Support 2 172.58
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
SIRI 5.07 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
ESSX 0.22 69.23%
MYRX 0.08 60.00%
CGEI 0.35 59.09%
LOCM 0.09 50.00%
RITT 0.03 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CARV 4.90 22.81%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)

SLXP Technical Analysis 5
As on 31st Mar 2015 SLXP Share Price closed @ 172.81 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 132.17 & Strong Buy for SHORT-TERM with Stoploss of 150.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
SLXP Target for April
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SLXP Other Details
Segment EQ
Market Capital 2245779712.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SLXP Address
SLXP
N/A
SLXP Latest News
Interactive Technical Analysis Chart Salix Pharmaceuticals, Ltd. ( SLXP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Salix Pharmaceuticals, Ltd.
SLXP Business Profile
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�s products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.